Multi-omics Analysis of Chronic Kidney Disease
1 other identifier
observational
150
1 country
1
Brief Summary
Chronic kidney disease (CKD) is a progressive disease with hidden epidemics and one of the most significant contributing factors to end-stage renal disease (ESRD), cardiovascular comorbidities, cachexia and anemia, which accounts for a nearly 1.2 million populations died per year.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2022
CompletedFirst Submitted
Initial submission to the registry
September 11, 2022
CompletedFirst Posted
Study publicly available on registry
September 16, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedSeptember 16, 2022
September 1, 2022
3 years
September 11, 2022
September 13, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Functional and structural alteration of microbiotas and their crosstalk with CKD-associated metabolism
Gut metagenome, fecal metabolome and serum metabolome were performed in this disease-severity classified CKD cohort, to identify the changes of microbial compositions and metabolism in CKD progression
baseline
Study Arms (4)
healthy controls
mild CKD
Moderate CKD
ESRD
Interventions
Eligibility Criteria
Inclusion Criteria: 1. Confirmed CKD patients. 2. Age≥18 years. Exclusion criteria： 1. Age\<18 years. 2. Patients with active gastrointestinal diseases, liver cirrhosis, cancer, active infection or cardiovascular event in the past 3 months, pregnancy or received renal replacement therapy.
You may qualify if:
- Age-matched and gender-matched HC with normal renal and liver function and not taking any medications were enrolled
You may not qualify if:
- Age\<18 years.
- Individuals with hypertension, diabetes, obesity, metabolic syndrome or pregnancy.
- Individuals who received gastrointestinal operation, antibiotics or probiotic products within one month.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Nephrolgoy, Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, 200072, China
Related Publications (1)
Wang H, Xue W, Cheng J, He Y, Song Y, Hu D, Peng A, Li C, Bao H. Altered fecal microbial and metabolic profiles reveal potential mechanisms underlying anemia in patients with chronic renal failure. Microbiol Spectr. 2025 Aug 5;13(8):e0316624. doi: 10.1128/spectrum.03166-24. Epub 2025 Jun 17.
PMID: 40525868DERIVED
Biospecimen
Fecal and serum samples were collected for metagenome and metabolome analysis
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Shanghai tenth People's Hospital
Study Record Dates
First Submitted
September 11, 2022
First Posted
September 16, 2022
Study Start
January 1, 2022
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
September 16, 2022
Record last verified: 2022-09